AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06738368
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06738368
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given CIV
Trial: NCT06587685
Drug: PG-011Gel
RxNorm normalized name: PG
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice daily for 52 weeks or 44 weeks
Trial: NCT05306873
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily~Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening~Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily
Trial: NCT05306873
Drug: Voclosporin
RxNorm normalized name: Voclosporin
DrugBank: Voclosporin (DB11693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weeks 1-24: 23.7 mg Voclosporin (3 x 7.9 capsules) twice daily
Trial: NCT05306873
Drug: Placebo for Voclosporin
DrugBank: Voclosporin (DB11693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weeks 1-24: 23.7 mg Placebo for Voclosporin (3 x 7.9 capsules) twice daily
Trial: NCT05306873
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stage 3 Dosing:~Participants who received placebo MMF in Stage 2:~* Week 1: Participants will receive 500mg MMF plus matching placebo for MMF (to appear like a 1000mg dose) twice daily~* Week 2: Participants will receive 500mg plus matching placebo for MMF (to appear like a 1000mg dose) and 1000mg in divided doses~* Weeks 3-24: 1000mg MMF twice daily~Participants who received MMF in Stage 2~• Week 1-24: 1000mg MMF twice daily
Trial: NCT05419583
Drug: Antiplatelet Drug (Aspirin or Statin)
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy for coronary artery disease
Trial: NCT06498583
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25 % ropivacaine ( 0.5ml / kg )
Trial: NCT05487807
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will be receiving nicotine therapy
Trial: NCT06739928
Drug: Irinotecan liposome (II) combined with adebrelimab and carboplatin
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan liposome (II) + adebrelimab + carboplatin
Trial: NCT06739928
Drug: etoposide combined with adebrelimab and carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: etoposide + adebrelimab + carboplatin
Trial: NCT05206201
Drug: ZY19489 Capsule
RxNorm normalized name: ZY19489
DrugBank: ZY19489 (DB18062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two part study with single and multiple dose
Trial: NCT05707403
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment T
Trial: NCT05176314
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Orally.
Trial: NCT05556798
Drug: Belantamab Mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belantamab mafodotin will be administered via IV infusion in an outpatient setting on Day 1 of Cycles 1-3. Treatment with belantamab mafodotin will be given at an initial dose of 1.0 mg/kg. The study will have a 3+3 dose escalation design for belantamab mafodotin. Belantamab mafodotin dose levels are 1.0 mg/kg, 1.4 mg/kg, and 1.9 mg/kg
Trial: NCT05556798
Drug: Nirogacestat
RxNorm normalized name: NIROGACESTAT
DrugBank: Nirogacestat (DB12005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:1 randomization between nirogacestat 100mg BID or 100 mg QD during the 4 day run-in period. Treatment with nirogacestat will be 100mg BID continuously during each cycle for all subjects.
Trial: NCT05556798
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After the 4-day run-in period, all patients will receive nirogacestat in combination with belantamab, mafodotin and pomalidomide. Pomalidomide was added for day 1-14 for cycle 1-3 and day 1-14 and day 21-35 for C4+.
Trial: NCT05807711
Drug: L-Methyl Folate and methylcobalamine
RxNorm normalized name: L-Methyl Dopa
DrugBank: Cobalamin (DB14098)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary supplement labeled to contain methylfolate 800 micrograms and methylcobalamine 1000 micrograms
Trial: NCT05733715
Drug: Pembrolizumab infusion
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg/ 4mL on Day 1 of each 3- or 6- week cycle (one 3 wk cycle; up to eight 6 wk cycles)
Trial: NCT05733715
Drug: Lenvatinib tablet
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg and 4mg daily for 21 days
Trial: NCT05097599
Drug: lorlatinib
RxNorm normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This arm of the Strata PATH trial will assess the clinical benefit of Lorbrena® (lorlatinib) in ALK and ROS1 gene fusion positive solid tumors, as detected by Strata testing, with the exception of NSCLC.
Trial: NCT05097599
Drug: encorafenib + binimetinib
DrugBank: Encorafenib (DB11718)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mektovi® (binimetinib) in BRAF p.v600X mutated solid tumors, as detected by Strata testing, with the exception of melanoma and colorectal cancer.
Trial: NCT05097599
Drug: talazoparib
RxNorm normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This arm of the Strata PATH trial will assess the clinical benefit of Talzenna® (talazoparib) in patients with advanced solid tumors harboring deep deletions or deleterious mutations with LOH in BRCA1/2 and PALB2, as detected by Strata testing, excluding HER2 negative breast cancer.
Trial: NCT04853368
Drug: ABBV-576
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT04853368
Drug: Galicaftor
RxNorm normalized name: Galicaftor
DrugBank: Galicaftor (DB14894)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT04853368
Drug: Navocaftor
RxNorm normalized name: Navocaftor
DrugBank: Navocaftor (DB19039)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT04853368
Drug: ABBV-119
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT05751421
Drug: Bupivacaine HCl 0.5% Injectable Solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: adductor canal block will be performed using bupivacaine before surgery
Trial: NCT02738073
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05097599
Drug: sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This arm of the Strata PATH trial will assess the clinical benefit of Trodelvy® (sacituzumab govitecan) in patients with advanced solid tumors and are Trop2 Treatment Response Score High (Trop2 TRS-H), as detected by Strata testing, excluding triple negative breast cancer, hormone receptor positive/ human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, metastatic urothelial cancer, non-small cell lung (NSCLC) cancer, small cell lung cancer (SCLC), head and neck cancer, colorectal cancer (CRC), and endometrial cancer.
Trial: NCT05097599
Drug: axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This arm of the Strata PATH trial will assess the clinical benefit of Inlyta® (axitinib) in patients with advanced solid tumors and are Angiogensis Inhibitor Treatment Response Score High (Angio TRS-H), as detected by Strata testing, excluding renal cell carcinoma, alveolar soft part sarcoma, and solitary fibrous tumors.
Trial: NCT05097599
Drug: Fam-Trastuzumab Deruxtecan-Nxki
RxNorm normalized name: fam-trastuzumab deruxtecan-nxki
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This arm of the Strata PATH trial will assess the clinical benefit of Enhertu ® in patients with advanced solid tumors with Her2 overexpression
Trial: NCT05097599
Drug: enfortumab vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This arm of the Strata PATH trial will assess the clinical benefit of Padcev® in patients with advanced solid tumors with nectin-4 overexpression
Trial: NCT06116409
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine was used for postoperative analgesia block.
Trial: NCT05683977
Drug: durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Visits will be completed at W0 (durvalumab in combination with chemotherapy initiation) and at regular visits approximately every 6 weeks during the induction period (durvalumab + PE) (W6 and W12), then every two months during the maintenance period (durvalumab alone) for the first year and every three months up to the end of follow-up or the final visit at M36.
Trial: NCT05038111
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: perioperative dexmedetomidine infusion
Trial: NCT04455958
Drug: Lopinavir/Ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03770663
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: American strategy Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL.
Trial: NCT06641154
Drug: GT-UGT1A1-AAV8-02
RxNorm normalized name: AAV8-RPGR
DrugBank: Cotoretigene toliparvovec (DB16797)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, single dose
Trial: NCT06195072
Drug: Amlitelimab
RxNorm normalized name: Amlitelimab
DrugBank: Amlitelimab (DB18835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP will be administered subcutaneously by the Investigator or designee as follows:~* Amlitelimab or~* Matching placebo
Trial: NCT06195072
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will take the active investigational product BI 1015550 or matching placebo provided as film-coated tablets, administered orally BID.
Trial: NCT06582706
Drug: Extended Release Niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg
Trial: NCT04680273
Drug: GDC-9545 Solution for Infusion
RxNorm normalized name: GDC-0425
DrugBank: GDC-0425 (DB14791)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B: 30 mg GDC-9545 as a solution for infusion, 3 mg/mL administered intravenously (IV) in 10 mL as an infusion over 30 minutes.
Trial: NCT06704633
Drug: Sacubitril / Valsartan Oral Tablet
RxNorm normalized name: sacubitril / valsartan Oral Tablet
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A 36-hour wash-out of ACE inhibitors before initiating ARNI will be done, because of a risk of angioedema if ARNI is started without a wash-out period. The ACE inhibitor or ARB will be switched to sacubitril/valsartan 50mg twice daily (24.3 mg sacubitril, 25.7mg valsartan) for two weeks, increased to 100mg twice daily for three weeks, followed by 200mg twice daily
Trial: NCT05899127
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5mg/kg induction，1.5 mg/kg/h maintenance
Trial: NCT05899127
Drug: 0.9%NaCl
RxNorm normalized name: triamcinolone acet/0.9%NaCl/PF 40 mg/mL INJECTION VIAL (ML)
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2mg/kg induction，1.5 mg/kg/h maintenance
Trial: NCT04882735
Drug: Acoramidis
RxNorm normalized name: Acoramidis
DrugBank: Acoramidis (DB17999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTR stabilizer administered orally twice daily (BID)
Trial: NCT05621070
Drug: JS002
RxNorm normalized name: Immunoglobulin g4, anti-(neural apoptosis-regulated convertase 1) (human monoclonal js002 .gamma.4-chain), disulfide with human monoclonal js002 .kappa.-chain, dimer
DrugBank: Ongericimab (DB18949)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS002 will be administered per auto-injector. Participants will receive JS002 every 2 weeks subcutaneously.
Trial: NCT05621070
Drug: JS002
RxNorm normalized name: Immunoglobulin g4, anti-(neural apoptosis-regulated convertase 1) (human monoclonal js002 .gamma.4-chain), disulfide with human monoclonal js002 .kappa.-chain, dimer
DrugBank: Ongericimab (DB18949)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS002 will be administered per auto-injector. Participants will receive JS002 every 4 weeks subcutaneously.
Trial: NCT05620628
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab will be administered at 1500mg every 4 weeks from cycles 1 day 1.
Trial: NCT05620628
Drug: Savolitinib
RxNorm normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savoritinib 600mg will be administered orally a day for 28 days as one cycle.
Trial: NCT05156047
Drug: Open-label pitolisant
DrugBank: Pitolisant (DB11642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.
Trial: NCT05156047
Drug: Double-blind pitolisant
DrugBank: Pitolisant (DB11642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.
Trial: NCT05278663
Drug: E6742
RxNorm normalized name: Eflornithine
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E6742 tablet.
Trial: NCT04463771
Drug: retifanlimab
RxNorm normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.
Trial: NCT04463771
Drug: epacadostat
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epacadostat will be administered orally BID.
Trial: NCT04463771
Drug: pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: pemigatinib will be administered orally QD.
Trial: NCT04463771
Drug: INCAGN02385
RxNorm normalized name: Anti-LAG-3 Monoclonal Antibody INCAGN02385
DrugBank: Tuparstobart (DB19118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCAGN2385 will be administered every 2 weeks
Trial: NCT04463771
Drug: INCAGN02390
RxNorm normalized name: INCAGN02390
DrugBank: Verzistobart (DB18895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCAGN2390 will be administered every 2 weeks
Trial: NCT06424756
Drug: Tempol
RxNorm normalized name: Tempol
DrugBank: Tempol (DB12449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During each experimental visit, intradermal microdialysis will be used to locally infuse Tempol (a superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
Trial: NCT06424756
Drug: L-NAME
RxNorm normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During each experimental visit, L-NAME (nitric oxide synthase inhibitor) will be perfused through microdialysis fibers for quantification of nitric oxide-mediated vasodilation.
Trial: NCT06424756
Drug: SNP - Sodium Nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At the end of each experimental visit, SNP will be perfused through microdialysis fibers to elicit a maximal vasodilation response.
Trial: NCT05504226
Drug: Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
RxNorm normalized name: Teneligliptin (as teneligliptin hydrobromide) 20 mg oral tablet
DrugBank: Teneligliptin (DB11950)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: To be orally administered once daily for 52 weeks.
Trial: NCT05504226
Drug: Teneligliptin Placebo Oral Tablet
RxNorm normalized name: placebo Oral Tablet
DrugBank: Teneligliptin (DB11950)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: To be orally administered once daily for 52 weeks. This arm will be switched to teneligliptin from week 24.
Trial: NCT06786208
Drug: Sunvozertinib
RxNorm normalized name: Sunvozertinib
DrugBank: Sunvozertinib (DB18925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sunvozertinb, a EGFR-TKI, 300mg QD oral
Trial: NCT05959239
Drug: TB006
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TB006 will be provided as single-use injectable glass vials.
Trial: NCT05113966
Drug: Trilaciclib
RxNorm normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-use, sterile powder to be reconstituted and further diluted with 250 milliliters (mL) of normal saline (sodium chloride solution 0.9%) or dextrose 5% in water (D5W)
Trial: NCT05113966
Drug: Sacituzumab Govitecan-hziy
RxNorm normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 milligram per kilogram (mg/kg) reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline
Trial: NCT04561206
Drug: Brentuximab Vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04868760
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
Trial: NCT00002022
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06379659
Drug: Growh hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In this group, patients will receive growth hormone solution containing 1.99 milligrams of the drug dissolved in 1.5 milliliters of 0.9% saline solution (normal saline), in addition to standard hormonal therapy, starting from cycle day 10. Treatment sessions will be conducted at two-day intervals. In case of non-response to treatment (failure to reach a minimum endometrial thickness of 7 millimeters in the subsequent assessment), the patient will receive a maximum of 4 doses, and if response to treatment is observed, growth hormone infusion will be discontinued. All infusions will be administered intrauterinely via an Intrauterine Insemination (IUI) catheter.
Trial: NCT06787586
Drug: ATTO-1310
RxNorm normalized name: ADALIMUMAB-ATTO
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ATTO-1310 Attobody
Trial: NCT05147194
Drug: Trimetazidine
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral，35mg bid
Trial: NCT04662112
Drug: NASOX
RxNorm normalized name: SODIUM CHLORIDE 1.2 mg in 10 mL NASAL SPRAY [NasoxinSpray]
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxalipatin 60 mg/m2 IV (2 h infusion) on Day 1, every 2 weeks Nal-IRI 50-60 mg/m2 IV (FBE, 90 min infusion) on Day 1, every 2 weeks S-1 40mg/m2 oral twice daily on Day 1-7, every 2 weeks
Trial: NCT05442554
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin IV infusion.
Trial: NCT05854966
Drug: CPI 613
RxNorm normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For INDUCTION therapy (14 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 14-day cycles for cycles 1 and 2 only.~For MAINTENANCE therapy (21 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 21-day cycles until progression, intolerable toxicity or withdrawal of consent.
Trial: NCT05854966
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For INDUCTION therapy (14 day cycles):~Metformin 500 mg daily (taken with meals), days 1-2 for cycle 1 only. Metformin 500 mg twice daily (taken with meals), days 3-14 for cycle 1 only. Metformin 1,000 mg daily (taken with meals), days 1-2 for cycle 2 only. Metformin 1,000 mg twice daily (taken with meals) days 3-4 for cycle 2 only.~For MAINTENANCE therapy (21 day cycles): Metformin 1,000 mg twice daily (taken with meals) days 1-21 until progression, intolerable toxicity or withdrawal of consent